Stealth BioTherapeutics is an innovative biopharmaceutical company dedicated to developing new biotherapeutic treatments for patients with genetic mitochondrial diseases and common diseases of aging. With a focus on mitochondrial dysfunction, our team is passionate about improving the quality of life for patients with diseases involving mitochondrial dysfunction, where there are currently no FDA-approved treatments available. We work closely with patients and advocacy organizations to better understand their journey and address the unmet needs in this field.

One area of our research focuses on ocular disease, particularly dry age-related macular degeneration (AMD), which is the leading cause of blindness among older adults in the developed world. This condition affects over 10 million individuals in the United States alone, yet there are no approved treatments available. Through our innovative therapies, we aim to provide hope and improved visual outcomes for these patients.

At Stealth BioTherapeutics, we are committed to patient-focused therapeutic development and driven by a desire to make a difference in the lives of those with unmet clinical needs. Join our high-energy and innovative team as we work towards our mission of advancing therapeutics for the benefit of patients worldwide